

# Juan C Pascual

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1456319/publications.pdf>

Version: 2024-02-01

84  
papers

3,167  
citations

136885

32  
h-index

175177

52  
g-index

95  
all docs

95  
docs citations

95  
times ranked

3247  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ayahuasca may help to improve self-compassion and self-criticism capacities. <i>Human Psychopharmacology</i> , 2022, 37, e2807.	0.7	8
2	A Functional Connectivity Study to Investigate the Role of the Right Anterior Insula in Modulating Emotional Dysfunction in Borderline Personality Disorder. <i>Psychosomatic Medicine</i> , 2022, 84, 64-73.	1.3	6
3	“Skills for pills”: The dialectical behavioural therapy skills training reduces polypharmacy in borderline personality disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 332-342.	2.2	7
4	Borderline personality traits mediate the relationship between low perceived social support and non-suicidal self-injury in a clinical sample of adolescents. <i>Journal of Affective Disorders</i> , 2022, 302, 204-213.	2.0	12
5	Predicting Non-Suicidal Self-Injury in Young Adults with and without Borderline Personality Disorder: a Multilevel Approach Combining Ecological Momentary Assessment and Self-Report Measures. <i>Psychiatric Quarterly</i> , 2021, 92, 1035-1054.	1.1	7
6	Ayahuasca as a Versatile Therapeutic Agent: From Molecules to Metacognition and Back. , 2021, , 1-19.		0
7	A genome-wide methylation study reveals X chromosome and childhood trauma methylation alterations associated with borderline personality disorder. <i>Translational Psychiatry</i> , 2021, 11, 5.	2.4	9
8	Structural brain abnormalities in borderline personality disorder correlate with clinical severity and predict psychotherapy response. <i>Brain Imaging and Behavior</i> , 2021, 15, 2502-2512.	1.1	9
9	Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain. <i>CNS Drugs</i> , 2021, 35, 1023-1032.	2.7	7
10	Decentering, Acceptance, and Non-Attachment: Challenging the Question “Is It Me?”. <i>Frontiers in Psychiatry</i> , 2021, 12, 659835.	1.3	2
11	Evidence for default mode network dysfunction in borderline personality disorder. <i>Psychological Medicine</i> , 2020, 50, 1746-1754.	2.7	13
12	Effects of mindfulness training on the default mode network in borderline personality disorder. <i>Clinical Psychology and Psychotherapy</i> , 2019, 26, 562-571.	1.4	18
13	Effects of Mindfulness Training on Borderline Personality Disorder: Impulsivity Versus Emotional Dysregulation. <i>Mindfulness</i> , 2019, 10, 1243-1254.	1.6	23
14	Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. <i>Psychopharmacology</i> , 2019, 236, 573-580.	1.5	48
15	Acceptance and present-moment awareness in psychiatric disorders: Is mindfulness mood dependent?. <i>Psychiatry Research</i> , 2019, 273, 363-368.	1.7	9
16	Orbitofrontal overactivation in reward processing in borderline personality disorder: the role of non-suicidal self-injury. <i>Brain Imaging and Behavior</i> , 2018, 12, 217-228.	1.1	34
17	Relationship between effortful control and facets of mindfulness in meditators, non-meditators and individuals with borderline personality disorder. <i>Personality and Mental Health</i> , 2018, 12, 265-278.	0.6	6
18	Four Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities: A Comparison Study With a Standard 8-Week Mindfulness Training Program. <i>Frontiers in Pharmacology</i> , 2018, 9, 224.	1.6	66

#	ARTICLE	IF	CITATIONS
19	Abnormalities in gray matter volume in patients with borderline personality disorder and their relation to lifetime depression: A VBM study. PLoS ONE, 2018, 13, e0191946.	1.1	20
20	Review and update on non-suicidal self-injury: who, how and why?. Actas Espanolas De Psiquiatria, 2018, 46, 146-55.	0.1	7
21	Factors predicting early dropout from dialectical behaviour therapy in individuals with borderline personality disorder. Actas Espanolas De Psiquiatria, 2018, 46, 226-33.	0.1	6
22	Fostering Self-Compassion and Loving-Kindness in Patients With Borderline Personality Disorder: A Randomized Pilot Study. Clinical Psychology and Psychotherapy, 2017, 24, 278-286.	1.4	77
23	Compassion and self-compassion: Construct and measurement. Mindfulness & Compassion, 2017, 2, 34-40.	0.5	26
24	Meditation Practice Is Associated with a Values-Oriented Life: the Mediating Role of Decentering and Mindfulness. Mindfulness, 2017, 8, 1259-1268.	1.6	24
25	Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management. Drugs, 2017, 77, 829-842.	4.9	102
26	Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. International Journal of Neuropsychopharmacology, 2017, 20, 698-711.	1.0	111
27	Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder. International Clinical Psychopharmacology, 2017, 32, 231-234.	0.9	19
28	Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatrica Scandinavica, 2017, 136, 323-331.	2.2	25
29	Direct experience while eating: Laboratory outcomes among individuals with eating disorders versus healthy controls. Eating Behaviors, 2017, 27, 23-26.	1.1	5
30	Exploring the relationship between non suicidal self-injury and borderline personality traits in young adults. Psychiatry Research, 2017, 256, 403-411.	1.7	21
31	Long-Term Course of Borderline Personality Disorder: A Prospective 10-Year Follow-Up Study. Journal of Personality Disorders, 2017, 31, 590-605.	0.8	45
32	Combining emotion regulation and mindfulness skills for preventing depression relapse: a randomized-controlled study. Borderline Personality Disorder and Emotion Dysregulation, 2017, 4, 13.	1.1	11
33	Converging Medial Frontal Resting State and Diffusion-Based Abnormalities in Borderline Personality Disorder. Biological Psychiatry, 2016, 79, 107-116.	0.7	57
34	Validation of the Spanish version of the McLean Screening Instrument for Borderline Personality Disorder. Revista De Psiquiatría Y Salud Mental (English Edition), 2016, 9, 195-202.	0.2	2
35	Impact of Mindfulness Training on Borderline Personality Disorder: A Randomized Trial. Mindfulness, 2016, 7, 584-595.	1.6	36
36	Validación de la versión española del McLean Screening Instrument for Borderline Personality Disorder. Revista De Psiquiatría Y Salud Mental, 2016, 9, 195-202.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. <i>Borderline Personality Disorder and Emotion Dysregulation</i> , 2016, 3, 1.	1.1	60
38	Ayahuasca: Pharmacology, neuroscience and therapeutic potential. <i>Brain Research Bulletin</i> , 2016, 126, 89-101.	1.4	135
39	Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. <i>Psychopharmacology</i> , 2016, 233, 823-829.	1.5	134
40	The role of hypothalamusâ€“pituitaryâ€“adrenal genes and childhood trauma in borderline personality disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 307-316.	1.8	43
41	Efficacy of cognitive rehabilitation on psychosocial functioning in Borderline Personality Disorder: a randomized controlled trial. <i>BMC Psychiatry</i> , 2015, 15, 255.	1.1	25
42	An exploratory association study of the influence of noradrenergic genes and childhood trauma in Borderline Personality Disorder. <i>Psychiatry Research</i> , 2015, 229, 589-592.	1.7	10
43	Exploring the relation between childhood trauma, temperamental traits and mindfulness in borderline personality disorder. <i>BMC Psychiatry</i> , 2015, 15, 180.	1.1	24
44	Parental Bonding in Subjects with Pathological Gambling Disorder Compared with Healthy Controls. <i>Psychiatric Quarterly</i> , 2015, 86, 61-67.	1.1	7
45	Effects of Dialectical Behaviour Therapyâ€“Mindfulness Training on Emotional Reactivity in Borderline Personality Disorder: Preliminary Results. <i>Clinical Psychology and Psychotherapy</i> , 2014, 21, 363-370.	1.4	39
46	Psychometric properties of the Spanish version of the Philadelphia Mindfulness Scale. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2014, 7, 157-165.	0.2	9
47	Asenapine in the treatment of borderline personality disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 120-123.	0.9	13
48	Exploring the interaction between childhood maltreatment and temperamental traits on the severity of borderline personality disorder. <i>Comprehensive Psychiatry</i> , 2014, 55, 311-318.	1.5	51
49	Propiedades psicomÃ©tricas de la versiÃ³n espaÃ±ola de la Philadelphia Mindfulness Scale. <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2014, 7, 157-165.	1.0	18
50	Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia caseâ€“control sample from Spain. <i>Schizophrenia Research</i> , 2014, 159, 107-113.	1.1	36
51	Association between methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. <i>Journal of Psychiatric Research</i> , 2014, 57, 34-40.	1.5	105
52	Testing the reinforcement sensitivity theory in borderline personality disorder compared with major depression and healthy controls. <i>Personality and Individual Differences</i> , 2014, 61-62, 43-46.	1.6	8
53	Assessing Decentering: Validation, Psychometric Properties, and Clinical Usefulness of the Experiences Questionnaire in a Spanish Sample. <i>Behavior Therapy</i> , 2014, 45, 863-871.	1.3	68
54	Relationship between Meditative Practice and Self-Reported Mindfulness: The MINDSENS Composite Index. <i>PLoS ONE</i> , 2014, 9, e86622.	1.1	96

#	ARTICLE	IF	CITATIONS
55	Validation of the Spanish version of the borderline symptom list, short form (BSL-23). BMC Psychiatry, 2013, 13, 139.	1.1	49
56	Emotional responses to a negative emotion induction procedure in Borderline Personality Disorder. International Journal of Clinical and Health Psychology, 2013, 13, 9-17.	2.7	14
57	Differences in attention and impulsivity between borderline personality disorder and bipolar disorder. Psychiatry Research, 2013, 210, 1307-1309.	1.7	21
58	Long-Term and Bizarre Self-Injurious Behavior. Journal of Psychiatric Practice, 2013, 19, 65-71.	0.3	3
59	Physiological and self-assessed emotional responses to emotion-eliciting films in borderline personality disorder. Psychiatry Research, 2012, 200, 437-443.	1.7	40
60	Effects of the dialectical behavioral therapy-mindfulness module on attention in patients with borderline personality disorder. Behaviour Research and Therapy, 2012, 50, 150-157.	1.6	76
61	Physiological Responses Induced by Emotion-Eliciting Films. Applied Psychophysiology Biofeedback, 2012, 37, 73-79.	1.0	89
62	Psychometric proprieties of Spanish version of Mindful Attention Awareness Scale (MAAS). Actas Espanolas De Psiquiatria, 2012, 40, 19-26.	0.1	59
63	Axis II comorbidity in borderline personality disorder is influenced by sex, age, and clinical severity. Comprehensive Psychiatry, 2011, 52, 725-730.	1.5	41
64	A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. International Clinical Psychopharmacology, 2010, 25, 349-355.	0.9	41
65	Psychotherapygenetic: Do Genes Influence Psychotherapy Adherence?. Revista De Psiquiatria Y Salud Mental (English Edition), 2010, 3, 68-71.	0.2	1
66	Quetiapine in the treatment of refractory irritable bowel syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 715-716.	2.5	5
67	Reply to effect of quetiapine XR on irritable bowel syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1164.	2.5	0
68	Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: A 3-month randomised controlled clinical trial. Behaviour Research and Therapy, 2009, 47, 353-358.	1.6	194
69	Neural correlates of impaired emotional discrimination in borderline personality disorder: An fMRI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1537-1545.	2.5	61
70	Stages of change in dialectical behaviour therapy for borderline personality disorder. British Journal of Clinical Psychology, 2008, 47, 417-426.	1.7	32
71	Utilization of psychiatric emergency services by homeless persons in Spain. General Hospital Psychiatry, 2008, 30, 14-19.	1.2	17
72	Failure to detect an association between the serotonin transporter gene and borderline personality disorder. Journal of Psychiatric Research, 2008, 42, 87-88.	1.5	30

#	ARTICLE	IF	CITATIONS
73	Discriminant Validity of the ZKPQ in a Sample Meeting BPD Diagnosis vs. Normal-Range Controls. <i>Journal of Personality Disorders</i> , 2008, 22, 178-190.	0.8	21
74	Immigrants and borderline personality disorder at a psychiatric emergency service. <i>British Journal of Psychiatry</i> , 2008, 193, 471-476.	1.7	30
75	Ziprasidone in the Treatment of Borderline Personality Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 603-608.	1.1	59
76	Hospitalization and Pharmacotherapy for Borderline Personality Disorder in a Psychiatric Emergency Service. <i>Psychiatric Services</i> , 2007, 58, 1199-1204.	1.1	32
77	Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study. <i>Actas Espanolas De Psiquiatria</i> , 2007, 35, 47-51.	0.1	9
78	The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes. <i>Actas Espanolas De Psiquiatria</i> , 2007, 35, 229-35.	0.1	38
79	Association between the serotonin transporter gene and personality traits in borderline personality disorder patients evaluated with Zuckerman-Zuhlman Personality Questionnaire (ZKPQ). <i>Actas Espanolas De Psiquiatria</i> , 2007, 35, 382-6.	0.1	17
80	Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. <i>Psychopharmacology</i> , 2006, 189, 145-153.	1.5	43
81	Injectable Atypical Antipsychotics for Agitation in Borderline Personality Disorder. <i>Pharmacopsychiatry</i> , 2006, 39, 117-118.	1.7	31
82	Dual diagnosis in the psychiatric emergency room in Spain. <i>European Journal of Psychiatry</i> , 2006, 20, .	0.7	27
83	Double-Blind, Placebo-Controlled Study of Dialectical Behavior Therapy Plus Olanzapine for Borderline Personality Disorder. <i>American Journal of Psychiatry</i> , 2005, 162, 1221-1224.	4.0	186
84	Ziprasidone in the Acute Treatment of Borderline Personality Disorder in Psychiatric Emergency Services. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1281-1283.	1.1	24